Alexion Pharmaceuticals (ALXN) Stock Research, Analysis & News

Quick Analysis on Alexion Pharmaceuticals (ALXN) Stock as of August 8, 2020

The Stock pays no dividend
Average trading volume is relatively low at 0
(See more information about Alexion Pharmaceuticals (ALXN) Stock below)

Alexion Pharmaceuticals (ALXN) Stock Profile Summary

Alexion Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of biologic therapeutic products in the United States, Europe, Latin America, Japan, and the Asia Pacific. It focuses on products for severe and life-threatening disease states, including hematologic, kidney, and neurologic diseases; transplant rejection; cancer; and autoimmune disorders. The company markets Soliris (eculizumab) for the treatment of patients with paroxysmal nocturnal hemoglobinuria, a blood disorder. It also conducts various Phase II clinical trials on Soliris for the treatment of atypical hemolytic uremic syndrome, MPGN II dense deposit disease, presensitized renal transplant, myasthenia gravis, neuromyelitis optica, multifocal motor neuropathy, and dry age-related macular degeneration. In addition, the company conducts preclinical studies on Soliris for the treatment of presensitized cardiac transplant, cold agglutinin disease, and catastrophic antiphospholipid syndrome. Further, its clinical programs include Samalizumab, which is in Phase I/II clinical trials for the treatment of chronic lymphocytic leukemia and multiple myeloma. Alexion Pharmaceuticals serves specialty distributors and specialty pharmacies, which supply physician office clinics, hospital outpatient clinics, infusion clinics, or home health care providers; government agencies; and hospitals, hospital buying groups, pharmacies, other healthcare providers, and distributors. The company was founded in 1992 and is headquartered in Cheshire, Connecticut.

Alexion Pharmaceuticals (ALXN) Stock Key Statistics Research and Analysis as of August 8, 2020

Alexion Pharmaceuticals (ALXN) Stock Competitor Research and Analysis

Abbott Laboratories (ABT)Baxter International Inc. (BAX)
Dyax Corp. (DYAX)Amgen Inc. (AMGN)
Biogen Idec Inc. (BIIB)Genzyme Corp. (GENZ)
Gilead Sciences Inc. (GILD)Life Technologies Corporation (LIFE)
Teva Pharmaceutical Industries Limited (TEVA)Watson Pharmaceuticals Inc. (WPI)
King Pharmaceuticals Inc. (KG)Mylan, Inc. (MYL)
Pfizer Inc. (PFE)Johnson & Johnson (JNJ)
GlaxoSmithKline plc (GSK)Sanofi-Aventis (SNY)
Novartis AG (NVS)AstraZeneca PLC (AZN)

Mutual Funds with Alexion Pharmaceuticals (ALXN) Stock in its top 10 holdings

FundCategoryALXN Holding Percentage
American Funds AMCAP F2Large Growth1.86%
American Funds New Economy ALarge Growth2.29%
ProFunds Biotechnology UltraSector InvTrading--Leveraged Equity3.37%
American Funds AMCAP 529ALarge Growth1.86%

ETFs with Alexion Pharmaceuticals (ALXN) Stock in its top 10 holdings

Stock Research on Alexion Pharmaceuticals (ALXN)

Latest Market News on Alexion Pharmaceuticals (ALXN)

Click here to find the latest news on Alexion Pharmaceuticals (ALXN)

Looking for Market Opportunties?

Today's Most Active Stocks
Today's Biggest Price % Gainers
Today's Biggest Price % Losers
Today's Unusual Rising Volume Stocks
Today's Unusual Falling Volume Stocks
Research Reports
Earning Calendar
ETF Center

See other companies in the same industry

Abbott Laboratories (ABT)
Baxter International Inc. (BAX)
Dyax Corp. (DYAX)
Amgen Inc. (AMGN)
Biogen Idec Inc. (BIIB)
Genzyme Corp. (GENZ)
Gilead Sciences Inc. (GILD)
Life Technologies Corporation (LIFE)
Teva Pharmaceutical Industries Limited (TEVA)
Watson Pharmaceuticals Inc. (WPI)
King Pharmaceuticals Inc. (KG)
Mylan, Inc. (MYL)
Pfizer Inc. (PFE)
Johnson & Johnson (JNJ)
GlaxoSmithKline plc (GSK)
Sanofi-Aventis (SNY)
Novartis AG (NVS)
AstraZeneca PLC (AZN)